Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension

Acne

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

J Am Acad Dermatol

Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG

doi: 10.1016/j.jaad.2025.11.031

Psoriasis

Mediterranean Diet and Patients With Psoriasis: The MEDIPSO Randomized Clinical Trial

JAMA Dermatol

Perez-Bootello J, Berna-Rico E, Abbad-Jaime de Aragon C, Goni L, Vazquez-Ruiz Z, Neria F, Cova-Martin R, Naharro-Rodriguez J, Ballester-Martinez A, Pindado-Ortega C, Monge D, Blauvelt A, Jaen P, Mehta N, Gelfand JM, Martinez-Gonzalez MA, Gonzalez-Cantero Á

doi: 10.1001/jamadermatol.2025.3410

Psoriasis

Efficacy and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial

Br J Dermatol

Paller AS, Fiorillo L, Becker E, Armesto S, Kontzias A, Oberoi RK, Zhang W, Amouzadeh H, Zhang Z, Arkin L

doi: 10.1093/bjd/ljaf305

Atopic Dermatitis

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

J Am Acad Dermatol

Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

doi: 10.1016/j.jaad.2025.05.1391

Allergic Diseases

Pragmatic Removal of Penicillin Allergy Electronic Health Record Labels: The PROPEL Trial A Randomized Clinical Trial

J Allergy Clin Immunol Pract

Stone CA Jr, Prigmore HL, McCoy AB, Stollings JL, Dear ML, Hiser W, Van Winkle G, Kripalani S, Wright A, Harrell FE, Rice TW, Lindsell CJ, Phillips EJ, Vanderbilt Learning Healthcare System Platform Investigators

doi: 10.1016/j.jaip.2025.07.006

Psoriasis

Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability

Adv Ther

Deodhar S, Loganathan S, Kadadanamari Subbarama Reddy R, Ranganna GM, Liu S, Hummel MA, Daniluk S, Hanczewska A, Vekovska K, Zegadlo-Mylik M, Pulka G, -Holz EW

doi: 10.1007/s12325-025-03240-5

Autoimmune Disease

A systematic review of clinical trial designs and outcome measures in Sjögren's disease randomized trials

J Rheumatol

Beydon M, Nguyen Y, Gordon R, Foulquier N, Bouillot C, Hammitt KM, Bowman SJ, Mariette X, Cornec D, McCoy SS, Seror R

doi: 10.3899/jrheum.2024-1012

Further Publications Dermatology

Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial

JAMA Dermatol

Ständer S, Yosipovitch G, Sofen H, Abramzon D, Galanter J, Wang S, Paolini JF

doi: 10.1001/jamadermatol.2025.4950

Systemic Lupus Erythematosus

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial

Ann Rheum Dis

Branch DW, Kim MY, Guerra MM, Worden J, Laskin CA, DeSancho MT, Landres IV, Knight JS, Slosberg HS, Minett M, Salmon JE

doi: 10.1016/j.ard.2025.02.012

Related content

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

Mediterranean Diet and Patients With Psoriasis: The MEDIPSO Randomized Clinical Trial

Efficacy and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Pragmatic Removal of Penicillin Allergy Electronic Health Record Labels: The PROPEL Trial A Randomized Clinical Trial

Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability

A systematic review of clinical trial designs and outcome measures in Sjögren's disease randomized trials

Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial